The experience with eribulin in real clinical practice from Moscow and Moscow region
Автор: Marphutov V.V., Filonenko D.V., Belonogov V.A., Andreyashkina I.I., Byakhov A.V., Kramskaya L.V., Karandeeva T.V., Mehtiyev V.N., Oskirko D.A., Suslova I.R., Skorina M.O., Romanchuk O.V., Samyshina M.A., Shikina V.E., Kozlov D.V., Hrupalo O.V., Tyuvinova E.V., Sherstnev V.M., Chernov I.S., Kolokolov J.J., Konopleva E.I.
Журнал: Злокачественные опухоли @malignanttumors
Рубрика: Оригинальные исследования
Статья в выпуске: 2 т.8, 2018 года.
Бесплатный доступ
Introduction. Eribulin, an non-taxane microtubule inhibitor, has been registered in Russia for patients with locally advanced or metastatic breast cancer (mBC) who received at least one chemotherapy regimen for a advanced disease, previous therapy should include anthracyclines and taxanes in adjuvant or metastatic setting, except the patients who could not be prescribed these drugs. We present our experience with eribulin in real clinical practice in Moscow and the Moscow Region. Patients and methods. We conducted a retrospective analysis of the experience with the use of eribulin in Moscow and the Moscow Region in 202 patients with mBC from January 2016 to February 2017 to assess the effectiveness and safety of the drug. All patients received previous therapy with anthracyclines and taxanes for locally advanced and / or metastatic cancer. The average age ьof patients at the time of inclusion in the analysis was 5 years (28-81). The status of the general condition on the ECOG 0-1 scale was registered in 81...
Eribulin, metastatic breast cancer, experience, safety, efficacy, real clinical practice
Короткий адрес: https://sciup.org/140243784
IDR: 140243784 | DOI: 10.18027/2224-5057-2018-8-2-21-30
